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ABSTRACT:
Increase in the incidence of multidrug-resistant Gram-negative bacterial strains pose 
a significant threat to healthcare system worldwide. New antibiotics are necessary to combat
particularly resitant pathogens. WHO’s global priority pathogens list was published in 2017 to
promote research and development of new antibiotics, as part of WHO’s efforts to address
growing global  resistance to  antimicrobial  agents.  Acinetobacter  baumannii,  Pseudomonas
aeruginosa  and  carbapenem-resistant,  third-generation  cephalosporin-resistant
Enterobacteriaceae were classified as highest priority pathogens requiring a new antibiotic
treatment  options.  Cefiderocol  is  a  novel  parenteral  siderophore cephalosporin that  shows
efficacy against listed Gram-negative bacteria. The results of the presented studies showed
that  cefiderocol  has  a  strong antimicrobial  effect  against  problematic  strains  that  produce
carbapenemases,  such  as  KPC  (K.  pneumoniae  carbapenemase)  and  B-class  
metallo-β-lactamases,  including  NDM-1  (New Delhi  metallo-β-lactamase),  as  well  as  the
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ESBL-producing strains. In addition, it does not require the use of the β-lactamase inhibitor.
The new agent demonstrates a favorable side effect profile. There is an urgent need to develop
new antibiotics.  Cefiderocol is  a  new antibiotic  that has a potential  to  effectively combat
particularly  resistant  bacteries  such  as  carbapenem-resistant  Acinetobacter  baumannii,
Pseudomonas aeruginosa, as well as carbapenem and 3rd generation cephalosporin-resistant
Enterobacteriaceae.
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Introduction:
The emergence of multi-drug resistant bacterial pathogens has led to a global threat to
public  health,  which  is  why,  we  urgently  need  new treatment  options  and  drug  delivery
systems. Cefiderocol is a new siderophor cephalosporin, conjugated with a catechol residue at
the  third  position  side  chain,  recently  developed,  in  order  to  control  various  bacterial
pathogens, including those resistant to β-lactams and espiecially to the carbapenems. Gram-
negative  bacteria  resistant  to  carbapenems are  of  utmost  priority  according to  WHO [1].
Cefiderocol has broad activity against Enterobacteriaceae and non-fermenting bacteria such as
Pseudomonas  aeruginosa  and  Acinetobacter  baumannii,  including  carbapenem-resistant
strains.  Cefiderocol  primarily  shows  affinity  for  penicillin  binding  protein  3  (PBP3)  of
Enterobacteriaceae  and  non-fermenting  bacteria,  an  essential  protein  of  the  divisome,
activating  peptide  cross-linking  between  the  glycan  chains  of  the  bacterial  cell  wall
peptidoglycan. 
The factors influencing the minimum inhibitory concentration (MIC) of cefiderocol
were  studied  with  different  mutant  strains.  Deficiency  of  iron  transporters  PiuA in  P.
aeruginosa or both CirA and Flu in Escherichia coli caused a 16-fold increase in MICs of
cefiderocol,  suggesting that these transporters assist  with outer membrane transfer of  the
drug.  Deficiency  of  OmpK35/36  in  Klebsiella  pneumoniae,  a  group  of  outer  membrane
porins, which made the strain more susceptible to some β-lactams, and overproduction of
efflux pump MexAB-OprM in P. aeruginosa demostrated no significant effect on the potentil
activity of cefiderocol [2].
Acinetobacter  baumannii  is  an important  non-fermenting species  of Gram-negative
bacteria,  which  shows  a  large  increase  in  resistance  to  carbapenems.  The  resistance  has
developed  by  the  acquisition  of  exogenous  enzymes,  activation  of  efflux  pump  and  a
deficiency  of  channels  porins  or  by  activation  or  an  additional  acquisition  of  OXA-type
enzymes [3,4,5]. Pseudomonas aeruginosa has a significant resistance, either endogenous or
exogenous, caused by an overproduction of a large number of efflux pumps, overproduction
of chromosomal β-lactamase AmpC, recovery of exogenous metalo-β-lactamases (MBL) and
the  porinal  OprD deficiency [8,9,10].  Stenotrophomonas  maltophilia  is  also  an  important
hospital pathogen, naturally resistant to many antibiotics and disinfectants, often with a high
degree of resistance due to various mechanisms, such as reduced permeability, β-lactamases,
aminoglycoside-modifying enzymes and efflux pumps. [11,12]
The aim of the work is a presentation of a potential new drug for multi-resistant Gram-
negative bacterial strains.
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A review of available research:
In vitro activity of Cefiderocol (S-649266) was evaluated in non-fermenting Gram-
negative bacteria  A. baumannii,  P.  aeruginosa and S.  maltophilia,  including defined drug-
resistant strains. Cefiderocol was synthesized in Shionogi & Co., Ltd. (Osaka, Japan). Two
types of global collection of clinical isolates of A. baumannii, P. aeruginosa and S. maltophilia
were  used  in  these  studies,  which  were  collected  by  two  internationally  recognized
microbiological  facilities:  International  Health Management  Associates,  Inc.  (Schaumburg,
IL,  USA)  and  JMI  Laboratories  (North  Liberty,  IA,  USA).  One  was  a  set  of  randomly
collected clinical isolates from the period 2009-2011, including 104 isolates of A. baumannii,
104 isolates of P. aeruginosa and 108 isolates of S. maltophilia. Another set was a collection
of strains resistant to β-lactams collected in 2000-2009, including 99 strains of A. baumannii
and  103  strains  P.  aeruginosa.  A.  baumannii  strains  were  resistant  to  carbapenems  (29),
resistant to ceftazidime (20), resistant to colistine (10) and MDR strains (30). P. aeruginosa
strains were resistant to carbapenems (10), resistant to ceftazidime (20), MBL (33) and MDR
(30). The activity of S-649266 was compared with the activity of meropenem, levofloxacin,
cefepime,  ceftazidime  and  piperacillin/tazobactam.  The  MICs  of  the  compounds  were
determined by microdilution on the medium.The obtained results indicate that S-649266 has a
stronger in vitro activity against  non-fermenting Gram-negative bacteria with significantly
lower  MIC90  values,  compared  to  ceftazidime,  meropenem,  levofloxacin,  cefepime  and
piperacillin/tazobactam [13].
In the study conducted by Akinobu Ito et al. the in vitro activity of cefiderecol against
Pseudomonas aeruginosa was increased in iron-depleted conditions. This study explains the
basic  mechanisms  responsible  for  the  strong  in  vitro  activity  of  cefiderocol  against  P.
aeruginosa. Cefiderocol showed a strong activity of the siderophore, and the catechol residue
on the side chain contributed to iron chelating activity. Due to its catechol group, cefiderocol
was  more  efficiently  transported  to  bacterial  cells  under  iron-free  conditions  than  under
conditions sufficient iron supply, resulting in increased in vitro activity against P. aeruginosa.
Based on the results of the study, conclusions were drawn: the in vitro antibacterial activity of
cefiderocol is increased in iron depleted media, and the catechol residue is important for the
antimicrobial activity of ceflerocol. This study proves that cefiderocol uses the P. aeruginosa
own  iron  transport  system  to  reach  its  site  of  action.  Catechol  part  of  the  agent  binds
extracellular iron, imitating the siderofor proteins of this bacterium. It has been shown that the
antibacterial activity of cefiderocol as well as uptake by P. aeruginosa cells is influenced by
the iron concentration in the medium, which is consistent with the fact that the expression of
outer membrane protein (IROMP) is increased under conditions of iron depletion [14].
Naoki Kohira et al. investigated the antimicrobial activity of S-649266 against various
clinical isolates of Enterobacteriaceae, including those producing carbapenemase. Two sets of
strain collections, a total of 850 clinical isolates of Enterobacteriaceae, were used to assess the
antimicrobial activity of cefiderocol. The first set consisted of 617 clinical isolates obtained
from various  regions,  including North  America,  Europe,  Africa,  Asia,  Latin  America,  the
South Pacific and the Middle East. It consisted of 106 E. coli isolates, 105 K. pneumoniae
isolates, 103 Serratia marcescens isolates, 100 Citrobacter freundii isolates, 100 isolates of
Enterobacter aerogenes and 103 isolates of Enterobacter cloacae. The second set included 233
strains  that  were  obtained  from various  regions,  including  North  America,  Europe,  Asia
Pacific, and Latin America. These strains were characterized by resistance to various β-lactam
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antibiotics  with  specific  mechanisms  associated  with  the  production  of  ESBL (extended
spectrum  β-lactamase)  of  class  A,  type  OXA  beta-lactamase  or  various  types  of
carbapenemases.  The  results  showed  that  with  regard  to  the  characterized  β-lactamase
producing strains, S-649266 has a strong antimicrobial effect against problematic strains that
produce carbapenemases, such as KPC (K. Pneumoniae carbapenemase) and class B metallo-
β-lactamases,  including  NDM-1  (New  Delhi  metallo-β-lactamase),  as  well  as  ESBL
producing strains. Cefiderocol does not require augmentation with the use of a β-lactamase
inhibitor. S-649266 is fairly stable against various β-lactamases, including ESBL and class B
carbapenemases (NDM-1, VIM and IMP) and class A (KPC, NMC and SME) [15]. 
The  in  vitro  activity  of  cefiderocol,  ceftazidime/avibactam,  ceftolozane/tazobactam
and  other  related  drugs  against  imipenem  resistant  Pseudomonas  aeruginosa,  imipenem
resistant Acinetobacter baumannii  and Stenotrophomonas maltophilia was examined. Non-
duplicated bacterial  isolates resistant  to imipenem P. aeruginosa,  resistant  to imipenem A.
baumannii  and S.  maltophilia  were analyzed. Impenem resistant P.  aeruginosa strains and
imipenem resistant A. baumannii strains were defined as isolates showing a MIC of ≥8 mg/L
of imipenem. MIC of cefiderocol was ≤4 mg/L for five isolates of resistant to colistin and
imipenem  P.  aeruginosa  and  70%  of  10  resistant  to  imipenem  A.  baumannii  strains.
Cefiderocol  showed  stronger  in  vitro  activity  than  ceftolozane/tazobactam  and  
ceftazidime/ avibactam against imipenem-resistant P. aeruginosa strains, imipenem-resistant
A. baumannii and S. maltophilia. [16]
Akinobu  Ito et  al. in  additional  evaluation  determined  the  effect  of  chromosomal
overproduction of AmpC on the in vitro activity of cefiderocol and MIC for isogenic mutant
strains  of  P.  aeruginosa  PAO1.  The  chromosomal  cephalosporinase  AmpC  is  a  type  of
mechanism of cephalosporin resistance that occurs with expposure to β-lactam antibiotics.
AmpC enzymes are inducible and can be expressed at high levels due to strain mutations.
Overexpression can result in a resistance to broad-spectrum antibiotics. This is due to the
inactivation of genes that regulate AmpC expression such as ampD and dacB. The MICs of
ceftazidime and cefepime for PAO1 were increased 4- to 16-fold by inactivation of ampD and
dacB, whereas inactivations had little effect for cefiderocol (≤2-fold increase for ampD or
dacB). Inactivation of the ampC gene on the MIC of the cefiderocol as well as ceftazidime
and had a limited effect (decrease ≤2-fold), in contrast to the imipenem, which showed an 8-
fold decrease in MIC. These results  suggest that the antimicrobial  activity of ceftazidime,
cefepime and imipenem are reduced by induced AmpC levels, while cefiderocol action is not.
Similar  results  were  presented  for  mutants  overproducing  AmpC,  isolated  from  clinical
isolates of P. aeruginosa and E. cloacae. The difference between the cefiderocol MIC values
for the parental strains and their derivatives was ≤4-fold (P. aeruginosa SR24 and E. cloacae
1480700). On the other hand, the MIC values for ceftazidime, cefepime and aztreonam for
Ampc producing isolates were 16 times or more than 16 times higher than for parental strains.
Cefiderocol  showed in  vitro  activity  against  AmpC overproducing strains,  low affinity  to
chromosomal  AmpC β-lactamases  and low tendency  to  induce  AmpC β-lactamases  of  P.
aeruginosa and E. cloacae over time. This may explain the strong antimicrobial activity of
cefiderocol against drug-resistant AmpC β-lactamase producing strains. [17]
A study  conducted  at  DaVita  Clinical  Research  in  Minneapolis,  Minnesota  and
Lakewood, Colorado, evaluated the pharmacokinetics and safety of cefiderocol in subjects
with impaired renal function. The results were assessed after a single 1000mg, intravenous, 1-
hour infusion of cefiderocol. Individuals with mild, moderate or severe and end-stage renal
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failure  requiring  hemodialysis  were  compared  demographically  (age,  sex  and  body  mass
index) with matched healthy subjects with normal renal function. The hemodialysis effect on
cefiderocol clearance was also evaluated.  The total  plasma clearance and terminal plasma
half-life  correlated  with  renal  function.  The  maximum  plasma  concentration  was  similar
between the groups with impaired renal function and the group with normal renal function.
About 60% of cefiderocol were removed by hemodialysis within 3 to 4 hours. The unbound to
plasma  proteins  fraction  was  similar  in  studied  groups  regardless  of  renal  function.  The
occurrence of adverse events does not seem to have any correlation with the degree of renal
failure. Single intravenous doses of 1000 mg of cefiderocol were generally well tolerated in
patients with renal impairment, with the exception of 1 patient, who had to had an infusion
discontinued, due to development of urticaria. Renal insufficiency affected the area under the
curve  of  concentration  versus  time,  total  clearance,  and  half-life,  without  affecting  the
maximum  concentration.  Cefiderocol  has  been  significantly  removed  by  sequential
hemodialysis. The results of this study suggest the need to adjust the dose of ceflerocol based
on renal function in patients with moderate and severe renal impairment and patients with
end-stage  renal  disease  and  the  need  for  an  additional  dose  in  patients  undergoing
hemodialysis [18]. 
James A.Karlowsky et al. determined the in vitro susceptibility of the collection from
2000-2016  consisted  of  8  954  Gram-negative  bacteria  isolates,  provided  by  100  clinical
laboratories  in  North  America  and  Europe  on  cefiderocol  using  clinical  and  laboratory
standards with the microdilution method. To test ceflerocol, Mueller-Hinton agar with reduced
iron content was used. The concentration of cefiderol inhibiting 90% isolates (MIC90) was
0.5/L (North America,  n=2470) and 1 mg/L (Europe; n=3543) for Enterobacteriaceae,  0.5
(North America; n=619) and 0.5mg/L (Europe; n=921) for Pseudomonas aeruginosa, 1 (North
America, n=308) and 2mg/L (Europe; n=664) for Acinetobacter spp., 0.5 (America North;  
n= 165) and 0.25 mg/L (Europe; n=175) for Stenotrophomonas maltophilia and 0.12 (North
America; n=40) and 0.5 mg/L (Europe; n=49) for Burkholderia cepacia complex spp. MIC of
cefiderocol was <4 mg/L for 99,9% (6005/ 6013) Enterobacteriaceae, 99,9% (1539/1540) P.
aeruginosa, 96,4% (937/972) Acinetobacter spp., 99.4% (338/340) S. maltophilia and 94.4%
(84/89) of Burkholderia cepacia complex spp. For the meropenem-insensitive isolates, the
MIC values for cefiderocol were ≤ 4 m/L for 99.6% (245/246) Enterobacteriaceae, 99.7%
(394/395) P.  aeruginosa,  96.1% (540/562) of Acinetobacter spp., and 87.1% (27/31) of B.
cepacia  complex spp. The results  suggest  that  cefiderocol  showed strong in vitro activity
(MIC,  ≤4 mg/L)  in  the  vast  majority  (99.4%,  8  903/8,954)  of  clinical  isolates  of  Gram-
negative bacteria in a multi-continental collection from 2000-2016, including those insensitive
to  carbapenems.  Additionally  no  cross  resistance  between  cefiderocol  and  colistin  was
observed [19]. 
The collection of carbapentem-resistant gram-negative bacteria isolated from clinical
specimens in 18 Greek hospitals has been tested for susceptibility to cefiderocol, meropenem,
ceftazidime,  cefepime,  ceftazidime  /  avibactam,  ceftolozane  /  tazobactam,  aztreonam,
amikacin,  ciprofloxacin,  colistin  and  tigecycline.  The  MIC  method  was  determined  by
microdilution.  A total  of  189  non-fermenting  Gram-negative  bacteria  (107  Acinetobacter
baumannii  and  82  Pseudomonas  aeruginosa)  and  282  Enterobacteriaceae  (including  244
Klebsiella pneumoniae, 14 Enterobacter cloacae and 11 Providencia stuartii) were examined.
In the case of both A. baumannii and P. aeruginosa, the MIC90 value of cefiderocol was 0.5
mg/L. For K. pneumoniae, E. cloacae and P. stuartii, the MIC90 of cefiderocol was 1,1 and
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0.5 mg/L, respectively. Tigecycline was the second most active antibiotic, and the third most
active antibiotic was colistin. [20]
Sean M. Stainton et al. evaluated the stability of humanized cefiderocol exposures in
vivo over 72 hours to pathogens with MICs for cefiderocol of 0.5-16 μg/ml in the mouse
model.  With  Acinetobacter  baumannii,  Pseudomonas  aeruginosa  and  Enterobacteriaceae
showing MIC values of 0.5-8 (n=11), enduring bactericidal activity was observed after 72
hours among 9 isolates. The MIC values after exposure revealed a single increase in two
dilutions compared to the control in one animal (1/54 sample, 1.8%) after 72 hours. Adaptive
resistance was not observed during therapy [21].
Simon  Portsmouthet  al.  evaluated  the  efficacy  and  safety  of  cefiderocol  against
imipenem-cilastatin in the treatment of complicated urinary tract infection in patients at risk
of  contracting  multi-drug  resistant  Gram-negative  bacteria.  A second-phase,  multicenter,
double-blind trial was conducted for parallel groups in 67 hospitals in 15 countries. Adults  
(≥ 18 years old) admitted to the hospital with a clinical diagnosis of complicated urinary tract
infections with or without pyelonephritis or those with acute uncomplicated pyelonephritis
were randomly assigned for intravenous, 1-hour infusions of cefiderocol (2g) or imipenem-
cilastatin  (1g each) three times a day, every 8 hours for 7-14 days. Patients were excluded if
they had an initial urine culture with more than two uropathogens, urinary tract infections or
pathogens known to be resistant to carbapenems. 452 patients were randomly assigned to
cefiderocol  (n=303) or  imipenem-cilastatin  (n=149),  of  whom 448 patients  (n=300 in the
cefiderocol group, n=148 in the imipenem-cilastatin group) received treatment. 371 patients
(n=252 patients in the cefiderocol group, n=119 patients in the imipenem-cilastatin group) had
a Gram-negative uropathogen and were included in the basic efficacy analysis. The primary
efficacy endpoint was achieved in 183 (73%) of 252 patients in the cefiderocol group and 65
(55%)  from  119  patients  in  the  imipenem-cilastatin  group  (p=0.0004),  determining  the
effectiveness of cefiderocol. Cefiderocol was generally well tolerated. Side effects occurred in
122 (41%) of 300 patients in the cefiderocol group and 76 (51%) of 148 patients from the
imipenem-cilastatin  group,  with  gastrointestinal  disorders  (i.e.  abdominal  pain,  nausea,
diarrhea, constipation, and vomiting) as the most common adverse reactions in both treatment
groups (35 [12%] patients in the cefiderocol and 27 [18%] patients in the imipenem-cilastatin
group).  The  intravenous  infusion  of  cefiderocol  was  no-inferior  than  that  of  imipenem-
cilastatin in the treatment of complicated urinary tract infection in people with multi-drug
resistant Gram-negative bacteria [22]. 
Conclusions:
Cefiderocol  offers  a  new  promising  treatment  option  against  multi-drug  resistant
strains of Gram-negative pathogens. Numerous studies confirm its stable pharmacokinetics
properties and efficacy against wide range of β-lactamases. The drug is currently in phase II
of clinical trials and the preliminary results are very promising. 
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